Xeris Pharmaceuticals Inc Stock News

Investors need to pay close attention to Xeris (XERS) stock based on the movements in the options market lately.

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) saw unusually large options trading activity on Friday. Traders purchased 5,536 call options on the company. This is an increase of 430% compared to the average daily volume of 1,044 call options. Several analysts recently issued reports on XERS shares. SVB Leerink started coverage on shares of Xeris Pharmaceuticals in a []

Northern Trust Corp cut its position in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) by 74.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,938 shares of the companys stock after selling 365,760 shares during the quarter. Northern Trust Corp owned about 0.19% of Xeris Pharmaceuticals [] The post Northern Trust Corp Sells 365,760 Shares of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) appeared first on ETF Daily News .

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) traded at $2.12 at last check on Tuesday, November 30, made an upward move of 3.68% on its previous days price. Looking at the stock we see that its previous close was $2.04 with the days price range being $2.04 $2.23. In terms of its 52-week price range, XERS Analysts Advise You To Maintain Your Position In Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Read More »

Xeris Biopharma Holdings, Inc. (XERS) with the stream of -5.99% also noticed, India TORM plc (TRMD) encountered a rapid change of 2.51% in the last hour of Mondays trading session. The post Have an attention on: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), TORM plc (NASDAQ:TRMD) appeared first on Stocks Equity .

Cubist Systematic Strategies LLC lessened its position in shares of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) by 22.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,230 shares of the companys stock after selling 13,785 shares during the quarter. Cubist Systematic []

Royal Bank of Canada boosted its stake in shares of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) by 3.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 286,803 shares of the companys stock after buying an additional 8,228 shares during the period. Royal Bank of Canadas holdings in Xeris Pharmaceuticals were worth $1,168,000 at the end of []

Xeris Biopharma Holdings, Inc. (XERS) with the stream of -0.91% also noticed, India Voyager Therapeutics, Inc. (VYGR) encountered a rapid change of -5.26% in the last hour of Friday’s trading … The post Stock Buzzers: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), Voyager Therapeutics, Inc. (NASDAQ:VYGR) appeared first on Stocks Equity .

Deltec Asset Management LLC grew its holdings in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) by 67.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 460,500 shares of the companys stock after purchasing an additional 185,000 shares during the quarter. Deltec Asset Management LLC owned []

The trading price of Xeris Biopharma Holdings Inc. (NASDAQ:XERS) floating lower at last check on Monday, November 22, closing at $2.18, -3.96% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

In the last trading session, 2.44 million shares of the Xeris Biopharma Holdings Inc. (NASDAQ:XERS) were traded, and its beta was 1.66. Most recently the companys share price was $2.27, and it changed around -$0.12 or -5.02% from the last close, which brings the market valuation of the company to $298.10M. XERS currently trades at Xeris Biopharma Holdings Inc. (NASDAQ: XERS): Would You Buy Today? Read More »

SVB Leerink assumed coverage on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a research report report published on Wednesday morning, Price Targets.com reports. The brokerage issued an outperform rating and a $6.00 price target on the stock. SVB Leerink also issued estimates for Xeris Pharmaceuticals Q4 2021 earnings at ($0.18) EPS, FY2021 earnings at ($1.29) EPS, []

Wall Street brokerages predict that Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will post earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Xeris Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.17). Xeris Pharmaceuticals reported []

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | P

Gainers Casper Sleep Inc. (NYSE: CSPR ) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The company also reported Q3 earnings results. Creative Realities, Inc. (NASDAQ: CREX ) gained 79.5% to settle at $2.62 as the company reported a merger with Reflect Systems on Friday. Patriot National Bancorp, Inc. (NASDAQ: PNBK ) climbed 50.4% to settle at $15.04. Patriot National Bancorp and American Challenger Development Corp. agreed to merge. Trio-Tech International (NYSE: TRT ) jumped 36% to settle at $6.73 after the company reported Q1 results, posting a 49% year-over-year increase in total revenue. SCYNEXIS, Inc. (NASDAQ: SCYX ) rose 25% to close at $6.75. SCYNEXIS, last week, posted a Q3 net loss of C$1.252 million. Matterport, Inc. (NASDAQ: MTTR ) gained 22.3% to close at $27.12. Newegg Commerce, Inc. (NASDAQ: NEGG ) surged 21.3% to settle at $19.21. After the closing bell, Newegg Commerces F-1 filing showed registration for a $300 million common stock offering.